Adoptive T-cell cancer therapy using chimeric antigen receptor (CAR)-expressing T cells has been successfully applied in the elimination of relapsed/refractory B-cell lymphoma and B-cell lymphocytic leukemia, as well as multiple myeloma, via the targeting of CD13 [153]. The gene discussed is ANPEP; the disease is plasma cell myeloma.